1. Home
  2. LUNG

as 12-20-2024 3:39pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Industrial Specialties

Nasdaq

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Founded: 1995 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 251.5M IPO Year: 2020
Target Price: $11.92 AVG Volume (30 days): 252.9K
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.47 EPS Growth: N/A
52 Week Low/High: $5.46 - $14.84 Next Earning Date: 02-19-2025
Revenue: $79,302,000 Revenue Growth: 22.34%
Revenue Growth (this year): 22.26% Revenue Growth (next year): 18.72%

LUNG Daily Stock ML Predictions

Stock Insider Trading Activity of Pulmonx Corporation (LUNG)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Rose Geoffrey Beran LUNG CHIEF COMMERCIAL OFFICER Dec 2 '24 Sell $6.19 4,376 $27,065.16 291,057
Lehman David Aaron LUNG GENERAL COUNSEL Dec 2 '24 Sell $6.19 5,497 $34,006.23 202,938
French Glendon E. III LUNG Director Nov 22 '24 Sell $6.63 20,000 $132,600.00 1,071,974
French Glendon E. III LUNG Director Oct 17 '24 Sell $6.52 20,000 $130,400.00 1,071,974

Share on Social Networks: